First‐in‐human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies
Sarina A. Piha‐Paul, Kyaw Zin Thein, Paul de Souza, Richard Kefford, Tara C. Gangadhar, Christopher M. Smith, Shelly Schuster, William C. Zamboni, Claire Dees, Ben Markman
Topics & Concepts
DocetaxelMedicineTolerabilityNeutropeniaPharmacokineticsDosingPopulationInternal medicineAnemiaPharmacodynamicsPhases of clinical researchDrugPharmacologyGastroenterologyAdverse effectOncologyChemotherapyEnvironmental healthCancer Treatment and PharmacologyNanoparticle-Based Drug DeliveryCancer therapeutics and mechanisms